Ocular Surface Disease in Patients with Ocular Hypertension and Glaucoma

REFERENCES

• Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334.
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–496.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355.
   PubMed Web of Science ®Google Scholar
• Stewart WC. Clinical Practice of Glaucoma. Thorofare, New Jersey: SLACK Inc., 1990.
   Google Scholar
• Ritch R. The Glaucomas. St. Louis: Mosby-Year Book, Inc., 1996.
   Google Scholar
• Stewart WC, Rhodes JS, Leech JN. Survey assesses red eye and prostaglandin use. Review Ophthalmol. Apr 2002;72–73.
   Google Scholar
• Tsai JH, Derby E, Holland EJ, et al. Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea. 2006;25:530–532.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572–579.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618–621.
   PubMed Web of Science ®Google Scholar
• Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593–1601.
   PubMed Web of Science ®Google Scholar
• Schmier JK, Covert DW. Characteristics of respondents with glaucoma and dry eye in a national panel survey. Clin Ophthalmol. 2009;3:645–650.
   Google Scholar
• Perry HD. Dry eye disease: Pathophysiology, classification, and diagnosis. Am J Manag Care. 2008;14(3 Suppl):S79–S87.
   Google Scholar
• Definition,and Classification Subcommittee of the International Dry Eye WorkShop. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75–92.
   Google Scholar
• American Academy of Ophthalmology, Preferred Practice Patterns. Cornea/External Disease Panel, Blepharitis. San Francisco, 2008.
   Google Scholar
• Tong L, Chaurasia SS, Mehta JS, et al. Screening for meibomian gland disease: Its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci. 2010;51:3449–3451.
   PubMed Web of Science ®Google Scholar
• Asbell PA, Lemp MA. Dry eye disease. In: The Clinician’s Guide to Diagnosis and Treatment. New York: Thieme, 2006.
   Google Scholar
• Baudouin C. Conditions bordering on allergy. J Fr Ophtalmol. 2007;30:306–313.
   Google Scholar
• Shah-Desai S, Sandy C, Collin R. Lax eyelid syndrome or ‘progeria’ of eyelid tissues. Orbit. 2004;23:3–12.
   PubMedGoogle Scholar
• Geerling G, Borrelli M. Adnexal surgery for severe ocular surface disease. Semin Ophthalmol. 2005;20:101–112.
   Google Scholar
• Henry JC, Peace JH, Stewart JA, et al. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613–621.
   PubMedGoogle Scholar
• Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–336.
   PubMed Web of Science ®Google Scholar
• Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80–86.
   PubMedGoogle Scholar
• De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85–94.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Lala E, Parier V, et al. Effect of preservatives on the conjunctiva: A comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients. J Fr Ophtalmol. 2003;26:675–679.
   Google Scholar
• Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies. Ophthalmology. 1999;106:556–563.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109–115.
   PubMed Web of Science ®Google Scholar
• Levrat F, Pisella PJ, Baudouin C. Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe. J Fr Ophtalmol. 1999;22:186–191.
   PubMed Web of Science ®Google Scholar
• de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: Epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232:221–224.
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.
   PubMed Web of Science ®Google Scholar
• Blondin C, Hamard P, Cholley B, et al. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res. 2003;27:253–259.
   PubMed Web of Science ®Google Scholar
• Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003;241:1037–1043.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: An ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360–1368.
   PubMed Web of Science ®Google Scholar
• Chigbu DI. The management of allergic eye diseases in primary eye care. Cont Lens Anterior Eye. 2009;32:260–272.
   PubMed Web of Science ®Google Scholar
• Pisella PJ. Pathology of the ocular surface. Rev Prat. 2006;56:1226–1231.
   Google Scholar
• Calonge M, Herreras JM. Clinical grading of atopic keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7:442–445.
   PubMed Web of Science ®Google Scholar
• Rao SK, Basti S, Lin A, et al. The itching, burning eye: Diagnostic algorithm and management options. Compr Ophthalmol Update. 2006;7:157–167.
   PubMedGoogle Scholar
• Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol. 1986;31:145–158.
   PubMed Web of Science ®Google Scholar
• Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin. 1987;27:27–35.
   PubMedGoogle Scholar
• Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118–122.
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology, Preferred Practice Patterns. Dry Eye Syndrome. San Francisco, 2008.
   Google Scholar
• Kramer P, York KK, Lubkin V, et al. Comparative levels of sex steroid hormones in lacrimal and salivary secretions and blood. Invest Ophthalmol Vis Sci. 1983;24:55.
   Google Scholar
• Mathers WD, Stovall D, Lane JA, et al. Menopause and tear function: The influence of prolactin and sex hormones on human tear production. Cornea. 1998;17:353–358.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998;17:38–56.
   PubMed Web of Science ®Google Scholar
• Lamberts DW. Dry eye and tear deficiency. Int Ophthalmol Clin. 1983;23:123–130.
   Google Scholar
• Norn M. The effects of drugs on tear flow. Trans Ophthalmol Soc UK. 1985;104:410–414.
   PubMedGoogle Scholar
• Thoft RA. Relationship of the dry eye to primary ocular surface disease. Trans Ophthalmol Soc UK. 1985;104:452–457.
   Google Scholar
• Labbé A, Baudouin C. Treatment of glaucoma in patients with dry eye syndrome. J Fr Ophtalmol. 2010;33:285–290.
   Google Scholar
• Anwaruddin R, Herrygers L, Noecker RJ. Effect of preservatives on the ocular surface in chronic glaucoma therapy. Invest Ophthalmol Vis Sci. 2002;43: E-Abstract 4088.
   Google Scholar
• Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339–343.
   PubMed Web of Science ®Google Scholar
• Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303–312.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837–845.
   PubMed Web of Science ®Google Scholar
• Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291–295.
   PubMedGoogle Scholar
• Mundorf T, Wilcox KA, Ousler GW 3rd, et al. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther. 2003;20:329–336.
   PubMed Web of Science ®Google Scholar
• Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;248:1757–1764.
   PubMed Web of Science ®Google Scholar
• Godfrey DA, Peplinski LS, Stewart JA, et al. A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:189–194.
   Google Scholar
• Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. Adv Ther. 2007;24:60–67.
   PubMed Web of Science ®Google Scholar
• Smith GT, Lee S, Taylor HR. Open evaluation of a new non-preserved artificial tear. Aust N Z J Ophthalmol. 1993;21:105–109.
   Google Scholar
• Detry-Morel M. Side effects of glaucoma medications. Bull Soc Belge Ophtalmol. 2006;299:27–40.
   Google Scholar
• Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: Brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther. 2007;23:372–376.
   PubMed Web of Science ®Google Scholar